Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 111,991

Document Document Title
WO/2016/072519A1
Provided is a cell population containing differentiated cells that can be obtained by inducing the differentiation of pluripotent stem cells, wherein the content ratio of undifferentiated pluripotent stem cells is 0.2% or less.  
WO/2016/071819A1
Embodiments of the invention relate to methods for treatment of age-related cognitive decline in a patient comprising administering to the patient a low dose of tetrahydrocannabinol (THC), preferably in an amount of 10-400 micrograms (µ...  
WO/2016/073828A1
Provided herein are methods for improving memory or cognitive function in a subject by administering a composition to the brain of the subject, where the composition comprises: i) a compound that increases expression of MALAT-1 long non-...  
WO/2016/073407A1
There are disclosed a series of quinuclidines having the Formula (I). which bind to the nicotinic α7 receptor and may be useful for the treatment of disorders of the central nervous system.  
WO/2016/073664A1
The disclosure is based on the discovery that aberrant immune responses are contributing to the pathogenicity of CCMs in patients, and that blocking those responses treats the CCM. Described herein is a method for treating CCMs in a pati...  
WO/2016/073889A1
The invention provides substituted imidazo[1,5-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gau...  
WO/2016/072392A1
The purpose of the present invention is to provide an agent for promoting tau protein production containing a natural substance as the active ingredient, a therapeutic or prophylactic drug for disease caused by tau protein deficiency, an...  
WO/2016/073420A1
The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range o...  
WO/2016/072522A1
The purpose of the present invention is to provide an agent for the prevention and/or treatment of Alzheimer's disease, the agent having a novel mechanism of action and reduced side effects. A polyphenol derivative having heightened lipo...  
WO/2016/073685A1
The present disclosure is directed to humanized anti-C1q antibodies and methods of using the same.  
WO/2016/067043A1
The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug d...  
WO/2016/066102A1
A use of maitake, maitake extract and/or maitake polysaccharide D component serving as an active ingredient in the preparation of an antidepressant drug; the drug is used to treat or prevent depressive disorder, and has a marked antidepr...  
WO/2016/067638A1
The present invention relates to novel compounds of a formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions comprising them and their use in therapy, for exampl...  
WO/2016/066115A1
Provided is a compound as shown by formula I having an enzyme activity which can inhibit endocannabinoid hydrolases NAAA and/or FAAH, pharmaceutically acceptable salts, hydrates or solvates thereof, and a preparation method and a use of ...  
WO/2016/067143A1
The present invention relates to carboxamide derivatives. More particularly, it relates to N-(2-alkyleneimino-3-phenylpropyl)acetamide derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, RA, RB,...  
WO/2016/065585A1
The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treat...  
WO/2016/065419A1
Provided herein are methods and compositions for use in the treatment of depression, anxiety or a depressive or anxiety-related disorder. Embodiments describe the administration of orotic acid or a salt thereof, or the administration of ...  
WO/2016/067629A1
The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ...  
WO/2016/068186A1
[Problem] To provide a new intestinal muscle layer thinning preventing/treating composition, diarrhea preventing/treating composition, and weaning stress alleviating composition. [Solution] The present invention was achieved after confir...  
WO/2016/069760A1
Treatment of dementia (e.g. Alzheimers disease) using a polynucleotide agent (e.g. DNA or RNA) that contains a nucleotide sequence that encodes a vascular endothelial growth factor (VEGF) polypeptide. The polynucleotide agent is administ...  
WO/2016/068267A1
Provided is an agent for improving sickness behavior symptoms. The agent for improving sickness behavior symptoms comprises a liver hydrolysate as an active ingredient.  
WO/2016/067265A1
The invention relates to the use of a reverse-transcriptase inhibitor in the prevention or treatment of a degenerative disease.  
WO/2016/069875A1
Provided are compositions comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate, or hydrate thereof, optionally in combination with a supplemental agent, and methods for reduc...  
WO/2016/065587A1
The present invention is directed to pyrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole compounds described herein in the potential treatment or prevention of neur...  
WO/2016/068616A1
The present invention relates to placenta-derived cells excreting C3 or C1R complement proteins, a pharmaceutical composition containing same, and a method for treating diseases using the placenta-derived cells. The placenta-derived cell...  
WO/2016/066755A2
The present invention refers to 4-amino-substituted pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine derivatives of formula I and IV able to target the Src family kinases (SFKs) such as Src, Fyn and Hck tyrosine kinases as well as ...  
WO/2016/066582A1
The present invention relates to method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solva...  
WO/2016/069801A1
Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include Bacteroides (e.g., B. fragilis, ...  
WO/2016/069510A1
The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential trea...  
WO/2016/067297A1
The compositions and compounds of formula I, formula II, formula III and formula IV which includes a salt of valproic acid or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as ph...  
WO/2016/065481A1
There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stim...  
WO/2016/066700A1
The present invention is directed to alpha-MSH analogues for treatment of neurodegenerative disorders.  
WO/2016/070181A1
Cotinine, a natural product present in tobacco leaves that has antidepressant effects on locomotor activity and sensorimotor abilities, was tested on depressive-like behavior, neuroinflammation and neurogenesis. When administered to mice...  
WO/2016/069854A1
Provided herein are compositions containing the drug OSU-03012 (AR-12) in combination with one or more drugs selected from multi-kinase inhibitors, HDAC inhibitors, folate antimetabolites, DNA alkylating agents, and sphingosine- 1 -phosp...  
WO/2016/066755A3
The present invention refers to 4-amino-substituted pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine derivatives of formula I and IV able to target the Src family kinases (SFKs) such as Src, Fyn and Hck tyrosine kinases as well as ...  
WO/2016/069898A1
Disclosed herein are delivery systems including coated and uncoated yarns, yarn precursors, threads, fibers, and other substrates for the constant or near-constant release of active compounds, as well as methods for manufacturing such de...  
WO/2016/063253A1
A method to provide prognosis of RRMS is disclosed. In presence of Gal-8 autoantibodies in the patient's blood sample a poor prognosis is given. The disclosure also provides a tool for healthcare professionals to make decision of startin...  
WO/2016/064997A1
Provided are methods for treating fatigue or depression in a subject that has a neurodegenerative disease, such as multiple sclerosis, and/or treating a neurodegenerative disease patient (e.g., a multiple sclerosis patient) presenting wi...  
WO/2016/063297A1
The present invention relates to the alkylidene phosphonate esters of formula I wherein, R1 is selected from a group consisting of hydrogen or alkyl group; R2 is selected from a group consisting of hydrogen, hydroxy, alkyl, alkoxy, nitro...  
WO/2016/063985A1
The present invention provides a production method for neural cells or nerve tissue, the method including steps (1)-(3): (1) a first step for culturing pluripotent stem cells in the absence of feeder cells in a culture medium that includ...  
WO/2016/063303A1
The present invention relates to the N-substituted beta-carbolinium compounds of general formula A and formulae I and II wherein, R1 and R2 groups are selected from halogens or trifluoromethyl; R3 group is selected from hydrogen or methy...  
WO/2016/064774A1
A method of improving neurological function in a human subject includes identifying a human subject diagnosed with at least one of post-CNS trauma, post-concussion syndrome, a chronic refractive epileptic encephalopathic condition, autis...  
WO/2016/064987A1
The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a B...  
WO/2016/062239A1
A method for promoting neurite outgrowth is provided by the invention, and the method comprises exposing the neurons to an effective amount of an immunomodulatory protein derived from Ganoderma, or a recombinant or a composition thereof....  
WO/2016/063995A1
In the present invention, compound such as (lR,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-flu orophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be usef...  
WO/2016/062688A1
The invention relates to bromodomain protein-inhibiting, in particular BET protein-inhibiting, preferably BRD4-inhibiting carboxamides of general formula (I), in which R1, R2, R3, R4 and R5 have the meanings specified in the description,...  
WO/2016/064711A1
This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need...  
WO/2016/063933A1
Provided is a heterocyclic compound that has an excellent RBP4 reducing effect and is useful as a preventive or therapeutic drug for diseases or symptoms mediated by a rise in RBP4 or by retinol supplied by RBP4. A compound represented b...  
WO/2016/062182A1
Disclosed is a pregabalin sustained-release preparation, wherein the sustained-release tablet consists of a pharmaceutically active ingredient containing pregabalin or a salt or hydrate thereof, a gel framework material containing algini...  
WO/2016/062860A1
The present invention relates to a pharmaceutical composition comprising amorphous vortioxetine hydrobromide, a process for the preparation thereof, use thereof and a method for stabilizing said pharmaceutical composition.  

Matches 301 - 350 out of 111,991